We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Tumor-Secreted Ligands Induce Fibroblast Behavior

By LabMedica International staff writers
Posted on 07 Nov 2018
Two chemical messengers have been identified that prompt pancreatic tumor-associated fibroblasts to adapt pro- or anti-cancer behavior properties.

Pancreatic ductal adenocarcinoma (PDAC) is poorly responsive to therapies and histologically contains relatively few cancer cells embedded within a dense mixture of extracellular components and noncancerous cells known as the stroma. More...
In pancreatic cancers, this fibrous material is particularly abundant, making up nearly 90% of the tumor mass. Within the stroma, cancer-associated fibroblasts (CAFs) secrete tropic factors and extracellular matrix components, and have been implicated in PDAC progression and chemotherapy resistance.

Investigators at Cold Spring Harbor Laboratory (Cold Spring Harbor, NY, USA) recently identified two distinct CAF subtypes characterized by either cancer promoting inflammatory phenotypes or cancer suppressing myofibroblastic ones. However, the mechanisms underlying their diversity and their roles in PDAC remain unknown.

For the current study, which examined the mechanism controlling fibroblast diversity, the investigators used organoid and mouse models to identify the chemicals TGF-beta and IL-1 as tumor-secreted ligands that promoted CAF heterogeneity.

They reported in the October 26, 2018, online edition of the journal Cancer Discovery that IL-1 induced specific enzyme expression and activation to generate inflammatory CAFs, and demonstrated that TGF-beta antagonized this process by downregulating IL-1R1 expression and promoting differentiation into cancer suppressing myofibroblasts.

"These cells can convert into one another, depending on the cues they get from the microenvironment and from the cancer cells," said first author Dr. Giulia Biffi, a post-doctoral researcher at Cold Spring Harbor Laboratory. "This is potentially useful because, in theory, you can shift the tumor-promoting cells to tumor-restraining, rather than just depleting the tumor-promoting cells. Ultimately, patients may benefit most from a combination of therapies that target both the cancer cells and parts of the microenvironment that support their growth."

Related Links:
Cold Spring Harbor Laboratory


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PlGF Test
Quidel Triage PlGF Test
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.